Medical expertise firm consolidates research administration on the Medidata Rave® Medical Cloud™By utilizing a consolidated platform, knowledge flows seamlessly between digital knowledge seize (EDC) and medical trial administration system (CTMS) solutionsClinical operations groups can give attention to important research oversight actions relatively than knowledge assortment and integrationLondon, UK: 1st Might 2019 – Medidata (NASDAQ: MDSO) right this moment introduced that medical expertise enterprise Smith & Nephew (LSE: SN, NYSE: SNN) has consolidated all of its international research on the Medidata Rave Medical Cloud. The corporate expanded its use of Rave medical options and can leverage Medidata Managed Providers to design and implement research globally.By adopting the Medidata Medical Cloud, Smith & Nephew has created a seamless knowledge move from digital knowledge seize (EDC) to medical trial administration system (CTMS) on a single platform. This simplifies trial oversight, offering medical operations groups with quick access and visualisation of information to know enrolment and progress of a medical trial.Medidata’s distinctive, data-driven CTMS ensures that Smith & Nephew can develop its research portfolio quicker by breaking down knowledge silos, permitting groups to give attention to oversight actions which can be important to the success of a trial. With this new performance, medical operations groups can: Enter knowledge as soon as and discover, entry, and reuse EDC knowledge every time necessaryEliminate expensive integrations, duplicate knowledge entry, knowledge reconciliation and guide monitoring activitiesAccess knowledge in actual time with a single signal on“Our expanded partnership with Medidata will set up a constant, unified method to handle all our medical trials as we increase our portfolio of superior medical merchandise to raised the lives of sufferers all over the world,” stated Andy Weymann, chief medical officer, Smith & Nephew.Smith & Nephew will work with Medidata’s managed providers crew to design and construct research within the areas of orthopaedics, sports activities drugs and superior wound administration.“We’re excited that Smith & Nephew selected to handle all of their research on the industry-leading Medidata Rave Medical Cloud,” stated Glen de Vries, president and cofounder, Medidata. “By making a seamless knowledge move between EDC and CTMS on a consolidated platform research groups have a single supply of reality and entry to knowledge in actual time, in any utility.”About MedidataMedidata is main the digital transformation of life sciences, with the world’s most-used platform for medical growth, business, and real-world knowledge. Powered by synthetic intelligence and delivered by {industry} specialists, Medidata helps pharmaceutical, biotech, medical machine corporations, and tutorial researchers speed up worth, minimise threat and optimise outcomes. Medidata and its corporations, Acorn AI and SHYFT, serve greater than 1,200 prospects and companions worldwide and empower greater than 150,000 licensed customers on daily basis to create hope for tens of millions of sufferers. Uncover the way forward for life sciences: www.medidata.comAbout Smith & NephewSmith & Nephew is a portfolio medical expertise enterprise with management positions in Orthopaedics, Wound, Sports activities Medication and ENT. Smith & Nephew has greater than 16,000 staff and a presence in additional than 100 nations. Annual gross sales in 2018 had been nearly $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For extra details about Smith & Nephew, please go to its company web site and comply with us on Twitter, LinkedIn or Fb.